Daiichi Sankyo Co., Ltd.

Founded as Sankyo Shoten through a joint investment by businessmen Matasaku Shiobara, Shotaro Nishimura and Genjiro Fukui

Launched digestive enzyme Taka-Diastase® (in 1894, Dr. Jokichi Takamine discovered the enzyme from a fungus)

Launched Adrenalin®, an adrenal cortex hormone agent

Established plant in Shinagawa, Japan

Dr. Umetaro Suzuki, a future Sankyo scientific adviser, made the world's first discovery of vitamin B1 (Orizanin®) in rice bran and established a foundation for the theory of vitamins

Changed company name from Sankyo Shoten to Sankyo Co., Ltd.

Appointed Dr. Jokichi Takamine as first president

Began manufacturing Japan's first synthetic agricultural chemical, the fumigant insecticide KOKUZOL®

Listed on Tokyo Stock Exchange

Launched LULU® cold medicine

Manufactured Chloromycetin®, the first antibiotic produced in Japan

Launched Sankyo Ichoyaku (now Daiichi Sankyo Ichoyaku)

Launched Vitamedin®, a vitamin B1, B6 and B12 compound

Established plant in Hiratsuka, Japan

Launched Krestin®, an anticancer drug

Launched Cefmetazon®, a cephamycin-type antibiotic

Launched Captoril®, the world's first renin-angiotensin-type hypertensive drug

Launched Zantac®, a therapeutic agent for peptic ulcers

Established Sankyo USA Corporation in New York City

Established Sankyo Europe GmbH in Dusseldorf, Germany

Launched Loxonin®, an analgesic and anti-inflammatory agent

Established plant in Onahama, Japan

Launched Regain®, a mini-bottled vitamin tonic

Globally launched Mevalotin®, a groundbreaking HMG-CoA reductase inhibitor (hyperlipidemic drug)

Launched antibiotic agent Banan®

Invested in Luitpold-Werk GmbH Group

Awarded the Ohkochi Memorial Grand Production Prize for Mevalotin®

Completed construction of head office building in Nihonbashi, Japan

Launched Acecol®, an antihypertensive agent

Established Sankyo Pharma Inc. in New Jersey, United States

Became the first pharmaceutical company in Japan to receive ISO 14001 environmental certification for its Onahama and Odawara plants

Established Sankyo Pharma Research Institute in California, United States for the development of new medicines

Launched Fastic®, a drug for lowering blood sugar

Launched Olmesartan (Benicar® in the United States and Olmetec® in Germany), an antihypertensive agent

Launched Calblock®, a long-acting calcium channel blocker

Launched Olmesartan in Japan

Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.

Began operations of Daiichi Sankyo Healthcare Co., Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH

Launched Urief®, a drug for dysuria (Daiichi Pharmaceutical Co., Ltd.)

Began operations on April 1, 2007 as Daiichi Sankyo Co., Ltd.

Acquired U3 Pharma GmbH of Germany and Ranbaxy Laboratories Ltd. of India

Launched Prasugrel, an antiplatelet agent and global product, in Februrary in Germany (as Efient®) and the United States in July (as Effient®)

Launched Prasugrel, an antiplatelet agent and global product, in Februrary in Germany (as Efient®) and the United States in July (as Effient®)

Launched TENELIA®, a therapeutic agent for type 2 diabetes

Launched natural tetrahydrobiopterin agent Biopten® Granules 10%

Launched oral antiplatelet agent Efient in Japan

Launched CANAGLU® Tablets 100mg for treatment of Type 2 Diabetes Mellitus

Received approval in Japan for additional AF and VTE indications for LIXIANA® (edoxaban)

Acquired biopharmaceutical company Ambit Biosciences

Launched edoxaban, an oral, once-daily anti-coagulant global product, in January in the United States (as SAVAYSA®) and in June in Europe (as LIXIANA®)

Launched Methylene Blue Injection 50mg, a treatment for methemoglobinemia

Launched MOVANTIK®, a treatment for opioid-induced constipation (OIC), in the United States via co-commercialization agreement with AstraZeneca

Ranbaxy Laboratories Limited acquired by Sun Pharmaceutical Industries Ltd. via all-stock transition

Launched edoxaban, an oral, once-daily anti-coagulant global product, in January in the United States (as SAVAYSA®) and in June in Europe (as LIXIANA®)

Daiichi Sankyo Healthcare acquired mail-order cosmetics and health food business, Im Co., Ltd.

Launched Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine for the prevention of diphtheria, pertussis, tetanus, and poliomyelitis (polio)

Launched antiepileptic agent Vimpat®

Launched CANALIA® for treatment of type 2 diabetes mellitus in Japan

Launched Tarlige® for treatment of pain in Japan.

Launched MINNEBRO® for treatment of hypertension in Japan

Launched TURALIO™ for treatment of select patients with tenosynovial giant cell tumor

Launched FLT3 Inhibitor VANFLYTA® in Japan

Launched ENHERTU® for patients with HER2 positive unresectable or metastatic breast cancer in the US and Japan. Refer to the Products page for information subsequently approved indications

New subsidiaries established in Australia, Canada, and Singapore

Launched EZHARMIA® in Japan as First Dual EZH1 and EZH2 Inhibitor Therapy for Patients with Adult T-Cell Leukemia-Lymphoma

Established research institutes in the Boston, USA, and Munich, Germany

Established new subsidiaries in Mexico and Colombia

Established “smart” research laboratory in San Diego, USA

Launched DATROWAY® in Japan as the First TROP2 Directed Therapy for Patients with Previously Treated Unresectable or Recurrent HR Positive, HER2 Negative Breast Cancer